Home / Companies / Kobayashi Pharmaceutical Co., Ltd. / 19 Feb 2025
Kobayashi Pharmaceutical Co., Ltd.: meeting of 19 Feb 2025
Votes reported on Form N-PX, item by item
32 Form N-PX filers reported votes at the Kobayashi Pharmaceutical Co., Ltd. meeting of 19 Feb 2025. Their records fall into 4 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSSecurity holder
Director elections (nominees put forward by security holders)
3 nominees; 82.7% of reported votes for; 7 filers withheld from or voted against at least one nominee.
142 vote records from 32 filers. 28 of the 31 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
CORPORATE GOVERNANCESecurity holder
Shareholder proposal: CORPORATE GOVERNANCE (A)
35 vote records from 25 filers. 17 of the 25 filers that marked the item either way voted against management.
CORPORATE GOVERNANCESecurity holder
Shareholder proposal: CORPORATE GOVERNANCE (B)
15 vote records from 7 filers. 1 of the 6 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
Several categoriesSecurity holder
Shareholder proposals (not separable from the filings)
Filers described these proposals in wordings that could not be matched to one another, so they are shown together.
8 vote records from 2 filers. 0 of the 2 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Proposal | 3. Proposal |
|---|---|---|---|
| Vanguard | For * | Against | No report |
| BlackRock and iShares | Against | No report | Against |
| Fidelity | For * | For * | No report |
| Dimensional | For * | For * | No report |
| State Street and SPDR | For * | Against | No report |
| Franklin Templeton | For * | For * | No report |
| Equitable | For * | For * | No report |
| Charles Schwab | For * | No report | Against |
| Nuveen and TIAA | Against | For * | No report |
| WisdomTree | For * | For * | No report |
| Northern Trust and FlexShares | For * | For * | No report |
| Lincoln Financial | For * | For * | No report |
| BNY Mellon | For * | For * | No report |
| MFS | For * | For * | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Kobayashi Pharmaceutical Co., Ltd. meeting?
32 Form N-PX filers reported votes at the meeting of 19 Feb 2025. 2 proposals from security holders could be told apart in the filings. The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Kobayashi Pharmaceutical Co., Ltd. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Kobayashi Pharmaceutical Co., Ltd.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Kobayashi Pharmaceutical Co., Ltd. with a meeting date within three days of 19 Feb 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.